Cancer and Leukemia Group B

癌症和白血病 B 组

• 批准号: 6602963
• 负责人: GINI F. FLEMING
• 金额: $ 31.97万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-09-30 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6602963
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trial phase II; clinical trial phase III; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; patient oriented research; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (provided by applicant): Participation in CALGB continues to be a major focus of the cancer research enterprise at the University of Chicago. This competing renewal proposes to continue and expand our extensive and broad involvement in the clinical, therapeutic and correlative science aspects of CALGB. Our commitment is to bring results of early testing of innovative therapeutic approaches and questions about clinical trials methodology to the cooperative group setting, where the standard of care for our patients is defined. We will continue to supply leadership for CALGB in terms of scientific committee leadership, administrative leadership, and study chairs. We will bring the results of translational research performed at the University of Chicago to the CALGB, and will supply core laboratories to assist CALGB in performing translational research. Young faculty and fellows will be trained in clinical research and encouraged to develop their careers through participation in CALGB. In addition, we will continue and improve our strong record of accrual to CALGB trials, both at the University of Chicago itself and through continued recruitment, education and support of community affiliates. We will continue and expand programs to reach out to minority patients in our immediate surroundings to offer them the opportunity for clinical trial participation. An overwhelming commitment to CALGB as a vehicle to improve the care of current and future cancer patients runs throughout clinical cancer research at the institution, and we look forward to helping bring the exciting developments of the basic science community to our cancer patients in the coming grant period.

描述（由申请人提供）：参与CALGB仍然是芝加哥大学癌症研究企业的主要重点。这种竞争性的更新建议继续和扩大我们在CALGB的临床，治疗和相关科学方面的广泛参与。我们的承诺是将创新治疗方法的早期测试结果和有关临床试验方法的问题带到合作组环境中，在那里定义我们患者的护理标准。我们将继续在科学委员会领导、行政领导和研究主席方面为CALGB提供领导。我们将把在芝加哥大学进行的转化研究成果带到CALGB，并将提供核心实验室，以协助CALGB进行转化研究。年轻的教师和研究员将接受临床研究培训，并鼓励他们通过参与CALGB来发展自己的职业生涯。此外，我们将继续并改善我们在CALGB试验中的良好记录，无论是在芝加哥大学本身，还是通过继续招募，教育和支持社区分支机构。我们将继续并扩大项目，接触我们周围的少数民族患者，为他们提供参与临床试验的机会。一个压倒性的承诺CALGB作为一种工具，以改善当前和未来的癌症患者的护理运行在整个临床癌症研究在该机构，我们期待着帮助带来基础科学界的令人兴奋的发展，我们的癌症患者在即将到来的赠款期。